Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Date:8/31/2013

duction in recurrent symptomatic VTE among patients with severe pulmonary embolism who were treated with edoxaban."

"We are excited about the results from the Hokusai-VTE study demonstrating that once-daily edoxaban may provide a new treatment option for a broad range of VTE patients. Daiichi Sankyo plans to submit New Drug Applications for edoxaban for VTE by the first quarter of 2014 in the U.S., Japan and Europe," said Glenn Gormley, MD, PhD, Global Head of Research and Development and Senior Executive Officer, Daiichi Sankyo. "Daiichi Sankyo is committed to continuing the global development of edoxaban and looks forward to the presentation of the results from the phase 3 ENGAGE AF-TIMI 48 study in patients with atrial fibrillation at the 2013 American Heart Association Scientific Sessions in November."

About Hokusai-VTE

Hokusai-VTE was a global, event-driven, randomized, double-blind, parallel-group phase 3 clinical study involving 8,292 patients in 439 clinical sites across 37 countries to evaluate once-daily edoxaban in patients with symptomatic DVT and/or PE.1

Patients were randomized to one of two different treatment groups. Both groups received open-label enoxaparin or unfractionated heparin for at least five days, and either warfarin or placebo (administered to edoxaban group), followed by double-blind edoxaban 60 mg (n=4,118) (edoxaban 30 mg for patients with renal impairment or low body weight or p-glycoprotein inhibitor use) or warfarin (n=4,122) for at least three months and up to a maximum of one year (duration of study treatment was determined by the investigator based on the patient's clinical features). Patients were followed for 12 months regardless of treatment duration to provide investigators with a better understanding of outcomes in clinical practice relative to an on-treatment analysis only.1

The primar
'/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
2. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
5. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
6. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
7. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
8. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
9. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
10. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
11. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 The consumer marketing playbook and ... sectors to better identify winning tools and techniques. ... with and understand consumers, as new technologies are ... purchasing decisions. According to recent ... area where organizations can observe a deep pool ...
(Date:7/11/2014)... 2014  Kindred Hospital Houston Northwest, with Wound ... of its new outpatient wound healing center.  The ... with chronic, hard to heal wounds. Chronic wounds ... amputation, lower leg wounds related to blood flow ... traumatic injury wounds which are complex and demonstrate ...
(Date:7/11/2014)... July 11, 2014  Veran Medical Technologies, ... today the positive, cost-effective final results for ... procedure. The SPiNPerc endobronchial percutaneous biopsy study ... approach to biopsy when a traditional bronchoscopic ... physicians experience positive financial outcomes when more ...
Breaking Medicine Technology:New Technologies Transforming Consumer Marketing Research Playbook 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Veran Medical Publishes Lung Cancer Patient Management Study 2
... Scientific Presentations Detail Progress with VeraTag(TM) Assays in Breast ... ... (Nasdaq: MGRM ) today announced five posters to be,presented at the 30th ... - 16, 2007. Following are details for,each embargoed session:, -- Friday, ...
... Tainted Research Grant Applications Must Be Rejected, Consumer,Advocates ... More apparent,conflict of interest violations in applications for ... were revealed today and the,Foundation for Taxpayer and ... to be rejected., The latest improprieties were ...
Cached Medicine Technology:Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 2Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 3New Conflict of Interest Violations Revealed at California Stem Cell Institute 2New Conflict of Interest Violations Revealed at California Stem Cell Institute 3
(Date:7/13/2014)... American water storage systems market is estimated to grow from ... a CAGR of 21.0%, from 2013 to 2018. The water ... North America. The U.S. is experiencing high growth on account ... collection, and the increased spending on modernization and upgradation of ... in Canada, and is rising at a rapid pace in ...
(Date:7/13/2014)... July 13, 2014 The report ... Molybdenum, Iron), Form (Chelated & Non Chelated), Application ... - Global Trends and Forecast to 2018” defines ... an analysis and forecasting of the global value ... the driving and restraining factors for the global ...
(Date:7/13/2014)... Fuel additives are chemicals, which are added ... kerosene, and so on, in order to enhance their ... corrosion effects caused by fuels and improving the combustion ... provide economies of scale in the long run, but, ... of the fuel products. , The various fuel additive ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on the ... rendering; Layout and Animation; Image Reconstruction]: Global Advancements, ... analyzes and studies the major market drivers, restraints, ... Europe, Middle East and Africa, Asia-Pacific and Latin ... of the 3D imaging market, providing an in-depth ...
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July ... sensor for people with diabetes is being developed to measure ... researchers report. Scientists at Brown University in Providence, R.I., ... It uses light, metal and a special enzyme that changes ... diabetics have to prick their fingers to draw blood to ...
Breaking Medicine News(10 mins):Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3
... of ... Haematology Business Assets, WAYNE, Pa., Nov. 13 Escalon Medical ... quarter ended,September 30, 2008., For the first quarter of fiscal ... in fiscal 2007. This,included product revenue of $8,669,000 for the first ...
... /PRNewswire-FirstCall/ - BELLUS Health Inc. (NASDAQ:,BLUS; TSX: BLU) announces ... Qualifications Staff of The NASDAQ Stock Market LLC (the,"Staff") ... The NASDAQ Global,Market to The NASDAQ Capital Market. The ... market on Friday, November 14, 2008. The Company will,continue ...
... RONKONKOMA, N.Y., Nov. 13 NBTY, Inc. (NYSE:,NTY) ... supplements, today announced that Arthur Rudolph, its Founder,and a ... pre-arranged stock,trading plan to sell a portion of his ... strategy of asset diversification and liquidity. The stock,trading plan ...
... Predictive medicine company,PreMD Inc. (TSX: PMD; PREMF.pk) ("PreMD" or the ... fiscal 2008 ended,September 30, 2008 ("Q3 2008")., During ... the PREVU* appeal is being reviewed by the FDA Commissioner,s ... the agreement with AstraZeneca has been terminated; - ...
... urging safe sex practices, study says , , THURSDAY, ... for pelvic inflammatory disease (PID) become highly vulnerable ... or months after treatment, researchers at Johns Hopkins ... the researchers, suggest that treating PID "with a ...
... Pharmos Corporation,(Nasdaq: PARS ) today announced that it ... 11, 2008 that the Company is not in,compliance with ... a minimum of $2,500,000 in stockholders, equity or,$35,000,000 market ... continuing operations for the most recently completed fiscal year ...
Cached Medicine News:Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 2Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 3Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 4Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 5Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 6Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 7Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 8Health News:BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market 2Health News:NBTY Founder Adopts Rule 10b5-1 Trading Plan 2Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 2Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 3Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 4Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 5Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 6Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 7Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 8Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 9Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 10Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 11Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 12Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 13Health News:Pelvic Inflammation Puts Girls at Risk for Repeat STIs 2Health News:Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter 2
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... Finnpipette Digital offers improved ergonomics for ... handle, modified grippy finger rest and ... comfort and efficiency. Finnpipette Digitals also ... gearing mechanism (pat. pend.) and super ...
Research Series 2100 Adjustable-volume Pipette,100-1,000 l, single-channel with adjustable-volume setting...
... The Sysmex pocH-100i is the first ... with low daily testing requirements. With its ... 3-part differential from just 15 L of ... for any small healthcare site including the ...
Medicine Products: